In ca
In case you are searching for a inventory that has a stable historical past of beating earnings estimates and is in a very good place to keep up the development in its subsequent quarterly report, you must take into account AbbVie (ABBV). This firm, which is within the Zacks Giant Cap Prescription drugs business, exhibits potential for an additional earnings beat.
This drugmaker has seen a pleasant streak of beating earnings estimates, particularly when wanting on the earlier two experiences. The typical shock for the final two quarters was 2%.
For the newest quarter, AbbVie was anticipated to put up earnings of $2.29 per share, but it surely reported $2.33 per share as a substitute, representing a shock of 1.75%. For the earlier quarter, the consensus estimate was $2.21 per share, whereas it really produced $2.26 per share, a shock of two.26%.
Worth and EPS Shock
With this earnings historical past in thoughts, current estimates have been transferring increased for AbbVie. The truth is, the Zacks Earnings ESP (Anticipated Shock…